ACROBiosystems社 Bispecific antibody opens a new era of immunotherapy
GPRC5D is a novel target for multiple myeloma (MM) immunotherapy. Under normal circumstances, its expression is limited to hair follicles, and it is specifically expressed in MM cells. The more advanced research targeting GPRC5D is the IgG4 bispecific antibody Talquetamab (JNJ-64407564) developed by Johnson & Johnson that targets GPRC5D×CD3, which activates CD3+ T cells and induces T cells to kill GPRC5D+ MM cells. Even in a model where BCMA escape occurs, it can also clear tumors and prolong survival.
The expression of CD20 on B cell-derived lymphoma, leukemia, and other tumor cells, and B cells involved in inflammatory and immune-related diseases makes it a potential therapeutic target for lymphoma, leukemia, and autoimmune diseases. Targeting CD20 and CD3 can offer a great prospect with regard to antibody drug development. In addition to monoclonal antibodies, pharmaceutical companies have turned the research and development of bispecific antibodies. It has set off a new upsurge in CD20×CD3 bispecific antibody drug development.
Fount of Information は、新商品、新規取扱メーカーなどの情報をいち早く紹介するコンテンツです。情報発信のスピードを重視しているコンテンツのため、現時点で法規制や取り扱いを確認できていない商品、定価を設定できていない商品があります。ご要望やご照会を受けた商品について、法令整備や在庫の充実を図ります。